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1. Introduction 
Data from cancer registries reported that cancer incidence is increasing every year and 
cancer claimed the second leading causes of death worldwide, surpassed only by 
cardiovascular disease. National Cancer Research Institute classified that the breast cancer 
ranks second as a cause of cancer death in women, followed by lung cancer. Globally, more 
than 1.1 million women are diagnosed with breast cancer every year at the same time nearly 
410, 000 women are queued for die due to the breast cancer (Cancer factors and Figures, 
2010, American Cancer Society). The incidence of breast cancer varies greatly around the 
world. Lowest breast cancer incidence was observed in less developed countries, whereas 
highest in the more developed countries. In United States alone, annually more than 240, 
000 women are diagnosed breast cancer and nearly 180, 000 women are diagnosed with the 
most deadly invasive breast cancer. It is also notable that about 1 in 8 women in the United 
States (12%) will develop invasive breast cancer of her life time. In 2010, an estimated 207, 
090 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., 
along with 54, 000 new cases of non-invasive (in situ) breast cancer. In addition, 
approximately 2000 men are expected to be diagnosed with invasive breast cancer in 2010. 
The survival rate for women diagnosed with localized breast cancer (cancer that has not 
spread to lymph nodes or other location in outside the breast) is 98%. If the invasive cancer 
that has spread to nearby or distant lymph nodes or organs, the five years survival is 84% or 
23%, respectively. However, the surprising result is the five year relative survival for female 
breast cancer patients has improved from 63% in the early 1960’s to 90% today.  
Women is primary risk factor for developing breast cancer, because, women’s naturally 
have more breast cells than men. The main reason for develop more breast cells in women 
due to the constant exposure of growth-promoting effects of the female hormones 
especially, estrogen and progesterone. Aside from being female, age is the most important 
risk factor for breast cancer.  Potentially modifiable risk factors include weight gain after age 
18. About 1 out of 8 invasive breast cancer are found in women younger than 45, while 2 out 
of 3 invasive breast cancer are common in women age 55 or older. Many studies have shown 
that being over weight adversely affects survival for postmenopausal women with breast 
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cancer risk and those women who are more physically active and less to die from the 
disease than women who are in active. The actual fact that only 20-30% of women are 
diagnosed with breast cancer has significant family history of breast cancer. However, a 
women’s risk of breast cancer approximately doubles if she has a first-degree relative 
(mother, sister, and daughter) who has been diagnosed with breast cancer. Apart from the 
family history of breast cancer, personal breast cancer history also a major risk factor for 
further onset. For an example, A women with cancer in one breast has a 3 to 4-fold increased 
risk of developing a new cancer in the other breast or other part of the same breast. This is 
unlike from first breast cancer recurrence.  
Mammography and ultrasonography are still the most effective for women with non-dense 
and dense breast tissues, respectively. Additionally, MRI, lymphatic mapping, the nipple-
sparing mastectomy, partial breast irradiation, neoadjuvant systemic therapy, and adjuvant 
treatment are promising for subgroups of breast-cancer patients. Although, there few drugs 
are commercially available, the well known tamoxifen can be offered for endocrine-
responsive disease, aromatase inhibitors are increasingly used. Assessment of potential 
molecular targets is now important in primary diagnosis. Tyrosine kinase inhibitors and 
other drugs with anti-angiogenesis and cancer cell metastasis inhibitors are currently 
undergoing preclinical investigations. Recent study show the experimental drug iniparib 
ultimately shrank tumors and increased the time they took to progress, in addition iniparib 
prolonging survival in women with what’s known as triple-negative breast cancers. This 
type of breast cancer lacks receptors for estrogen and progesterone and doesn’t have large 
quantities of HER-2/neu protein, which the most successful cancer therapies target. This 
means that may currently available drugs simply won’t affect it. Therefore, new class of 
chemotherapeutic drug that can potentially inhibit the growth of estrogen-nonresponsible 
breast cancer are highly warranted.  
The indigenous Taiwanese medicinal mushroom A. camphorata (Syn, Antrodia cinnamomea; 
Taiwanofungus camphoratus), locally known as “Niu Chang Chih” is a parasitic fungus grown 
in the inner cavity on the aromatic tree Cinnamomum kaneirai Hay (Lauraceae). This species 
is endemic to Taiwan and has been widely used as a Chinese folk medicine and functional 
food. In Taiwanese culture, it is believed that Niu Chang Chih is a valuable gift from the 
haven. Thereby, it claimed “National treasure of Taiwan”. This species was first published 
by Zang & Su (1990). Dr. Su, a residential chemist, knew Niu Cheng Chih” very well from 
his chemical studies of various medicinal fungus (Wu et al., 1997)  A. camphorata is starting 
to attract interest due to their abundant bioactive phytocompounds including, triterpenoids, 
flavonoids, polysaccharides, maleic/succinic acid, benzenoids and benzoquinone 
derivatives. The current scientific world’s particular interest in A. camphorata and its curative 
properties originated from the realm of traditional practice. Till the dates there are more 
then three hundred scientific reports were published regarding the therapeutic potential of 
A. camphorata or it’s derived pure compounds. Both the fruiting bodies and mycelium of A. 
camphorata has been shown to exhibit a wide range of health promoting benefits for the 
hepatic, neurological and cardiovascular systems. It also shown to inhibit variety of 
inflammation, viral infection, oxidative stress, atheroslerosis and the growth of a variety of 
cancer cells (Ao et al., 2009; Geethangili & Tzeng, 2009).  
1.1 Clinical studies on A. camphorata as an adjuvant therapy for cancer 
The anticancer potential of A. camphorata was recognized as early as 2002, when it was 
shown to inhibit proliferation and enhanced apoptosis in cultured human premyelocytic 
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leukemia HL-60 cells (Hseu et al., 2002; 2004). Thereafter extensive studies have verified the 
cancer-preventing or anti-cancer properties of A. camphorata and their derived pure 
compounds in various murine models of human cancer cell lines. Both the fruiting bodies 
and mycelium of A. camphorata have potent anti-proliferative activity against various 
cancers in vitro and in vivo (Table. 1). Its chemopreventive action against various cancer cells 
via modulating multiple signaling pathways at various cellular levels, the ultimate outcomes 
of which are apoptosis, call cycle arrest, growth inhibition, anti-angiogenesis and  inhibition 









Fig. 1. Molecular targets of A. camphorata on various cancers 
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Table 1. Anti-cancer activity of A. camphorata and it’s components against various cancer 
models 
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2. A. camphorata regulates cell cycle progression 
In mammalian cells, cell cycle progression is tightly coordinated by the cyclin-dependent 
protein kinases (Cdk1, Cdk2, Cdk4 and Cdk6), regulatory cyclin subunits (cyclin-A, cyclin-
B, cyclin-Ds and cyclin-E) and their inhibitors including p21WAF1 and p27KIP1 (Athar et al., 
2009). Cyclin-E/Cdk1 (Cdc2) complex is the key components of the cell cycle check point 
pathway that delays mitotic entry in response to stalled replication or DNA damage. In 
addition to Cdk1, cyclin-Ds/Cdk4/6, and cyclin-A/Cdk2 are also required for G1/S 
transition and progression through S phase, while cyclin-A,B/Cdk1 complex activates are 
required for entry into mitosis (Fig. 1). Although, cyclin-B/Cdk1 complex are maintained 
inactive during interphase through the phosphorylation of Cdk1 at Thr 14 and Tyr 15 
residues, which are catalysed by Wee1 and Myt1 (Thomas et al., 2005). Cyclin-D1 is a rate 
limiting activator for the G1/S transition, another cell cycle check point. The G1/S transition 
requires the activation of the cyclinD/Cdk4/Cdk6 and cyclin-E/Cdk2 complexs, which in 
turn phosphorylates the retinoblastoma protein (Rb). The subsequent dissociation of E2Fs 
from Rb activates a serious of target genes that are required for cell entering S phase (Athar 
et al., 2009). Rb was the first tumor suppressor gene, which is essentially 
hypophosphorylated when cells are in G0 and become progressively phosphorylated by G1 
phase cyclin/Cdk complexes as cells enter G1, becoming hypophosphorylated on a larger 
number of serine and thrionine residues as cells advance through the R point., Rb remaines  
hypophosphorylated through the reminder of the cell cycle. The phosphorylate groups on 
Rb are removed by the protein phosphatase (PPI) as cells exit mitosis. Therefore, Rb plays a 
critical role in cell cycle progression as the molecular governor of the R-point transition 
(Mathhews & Gerritsen, 2010). Besides, Cdk2 activation, entry into mitosis requires nuclear 
translocation of active Cdc2/cyclin-B1 complexes. Normally, most Cdc2/cyclin-B1 
complexes accumulate in the nucleus during prophase while Cdc25C phosphatase activates 
them by dephosphorylating Cdc2 on both Thr14 and Tyr15 (Thomas et al., 2005).  
Cell cycle kinases are frequently upregulated in human cancer due to the over expression of 
their cyclin partners or inactivation of the Cdks inhibitors. Indeed, deregulation of cyclin-
D1-Rb axis is very common in human cancers as cyclin-D1 accumulation is found in various 
types of human malignancies including breast, skin, lung, liver etc., and affect cell cycle 
modulation perhaps its most extensively studied target (Athar et al., 2009). Number of 
researchers has been reported on the cancer preventive and therapeutic effects of A. 
camphorata in different in vitro and in vivo test models. As summarized in Table. 1, various 
parts including mycelium and fruiting body, extracts (ethanol, methanol and ethyl acetate 
extracts) and chemical ingredients such as polysaccharides, triterpinoids, sesquiterpine, 
steroids, phenol compounds, adenosine, cordycepin, ergosterol etc., possessed potent 
anticancer activity. Besides, breast cancer cells are highly resistant to chemotheraphy, and 
there is still no effective cure for patients with advanced stages of the disease, specifically in 
cases of hormone-independent cancer (Rao et al., 2011). In addition, the cost of this therapy 
is significant, and therefore  
The inhibition of breast cancer cell proliferation by A. camphorata was strongly associated 
with cell cycle arrest and/or induction of apoptosis. Exposure of human breast cancer cells 
(MCF-7) against A. camphorata caused significant arrest of cell progression (Fig. 2) in G1 
phase (Yang et al., 2006).  It was further confirmed by estrogen non-responsive human 
breast cancer cell line (MDA-MB-231) showed that approximately 70% of A. camphorata 
treated MDA-MB-231 cells were arrested in sub-G1 (Fig. 2) phase (Hseu et al., 2008). It has 
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been documented that A. camphorata also arrest androgen-responsive-LNCaP and androgen-
independent PC-3 human prostate cancer cells in a similar G1/S (Fig. 2) phase arrest (Chen 
et al., 2007), but caused G0/G1 arrest in human hepatoma HepG2 cells (Song et al., 2005), 
whereas, human urinary bladder cancer (T24) cells were arrested in G2/M (Fig. 2) phase 
(Peng et al., 2007). The reasons as to why A. camphorata causes G1 arrest in breast cancer 
cells, but G2/M phase arrest in other cells are still unknown. Therefore, A. camphorata has 
been shown to modulate the major cell cycle mediators at lower microgram concentrations, 
arresting breast cancer cells at the G1/S phase of the cell cycle. The anti-proliferative activity 
of A. camphorata involves the induction of p21WAFl and p27KIP1 and down-regulation of 





Fig. 2. Schematic diagram of A. camphorata-induced cell cycle arrest in various cancer cells  
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3. A. camphorata regulates apoptosis and cell survival 
The major strategies of the underlying case of cancer was attributed to accelerated or 
dysregulated proliferation leading to cellular expansion and accumulation of tissue mass. It 
is well understood that key regulators of the cell cycle are frequently altered in many tumor 
types, with a consequent impact on elements of proliferative control such as cell cycle 
checkpoints and the response to DNA damage. Therefore, modern chemotherapeutic 
approaches are designed to exploit such aberration to induce cytotoxicity and tumor 
regression or cytostasis to control tumor progression.   Uncontrolled cell proliferation, 
however, is only part of the picture. Recent cancer research progress has broadened our 
understanding underlying etiology to encompass aberrant cellular survival, as a 
consequence of failing to appropriately induce apoptosis or cell death, which are major 
contributor to the transformed state. Apoptosis, also known as programmed cell death, is a 
well-regulated and ordered process that occurs both in development and in response to 
stress to help maintain tissue homeostasis. Environmental and physico-chemicals stimulates 
accumulation of mutations or carcinogens that critically alter cell proliferation, cell cycle 
regulation, cell-cell or cell-extra cellular matrix (ECM) interactions, which eventually leads 
malignancy. However, apoptosis induction helps to prevent malignancies via eliminating 
damaged cells (Leibowitz & Yu, 2010).  Apoptosis occurred via multiple pathways, and the 
extrinsic death receptor-mediated and the intrinsic mitochondrial-mediated cell death 
pathway (Fig. 3) are the ones better characterized in molecular terms (Fulda & Debatin, 
2006). 
The role of mitochondria as principal crossroad of the apoptotic process and emerged since 
1990’s, when it was shown that mitochondria of apoptosing cell death (Ghibelli & Diederich, 
2010). The intrinsic pathway is characterized by the rapid release of cytochrome c from the 
mitochondrial inner membrane space into the cytosol. This critical event is absolutely 
required for caspase-dependent cell death (Kasibhatla & Tseng, 2003).  The term 
mitochondrial outer membrane permeabilization (MOMP) was coined (Green & Kroemer, 
2004), which indicates release of inter-membrane proteins rather than ion passage. However, 
the topological features and size concerns questioned about cytochrome c release via 
phospholipids transfer protein (PTP). A channel linking the inter-membrane mitochondrial 
space to the cytosol was sought to explain release of cytochrome c. The release of 
cytochrome c also depended activation of pro-apoptotic proteins such as Bax/Bid, which 
was stimulated by physico-chemical-induced cell stress. During the stimulation, cytochrome 
c nucleates the assembly of a multi-protein complex, known as apoptosomes, functionally 
analog to the DISC, further recruits and activates the other upstream caspases, including 
caspase-9 and caspase-8. Caspase-8 and caspase-9 converge into proteolytic activation of 
caspase-3, results cells undergo execution phase of apoptosis and/or cell dismantling 
(Ghibelli & Diederich, 2010).   
Number of investigations critically characterized the anticancer potential of A. camphorata, 
regarding to the potential cytotoxic effect of various cancer cells derived from different 
human origins including lung, liver, breast, prostate, colon and oral cells (Table. 1). The 
viability of these cancer cells was significantly decreased by A. camphorata treatment in a 
dose-dependent manner. However, different cancer cells responded to A. camphorata with 
different sensitivities. A crude aqueous extract obtained from the fermented culture broth of 
A. camphorata exerted a potent effect in reducing the viability of different human breast 
cancer cell lines, including estrogen-responsive MCF-7 and estrogen-nonresponsive MDA-
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MB-231 cells with an IC50 value of 57 and 136 µg/mL, respectively (Yang et al., 2006; Hseu et 
al., 2008; Yang et al., 2011). Meanwhile, the highest dose of A. camphorata (>100 µg/mL) was 
used to treat normal human endothelial cells for 24 hours, there was no cytotoxic effects 
were found. Furthermore, the chloroform extracts of fruiting bodies of A. camphorata 
significantly inhibited the growth of human breast cancer (MCF-7) cells with an IC50 value of 
65 µM (Rao et al., 2007). This indicated the differential cytotoxic effects of A. camphorata 
crude extract on different kinds of breast cancer cells, with no harmful effects on normal 
cells at higher concentrations (Hseu et al., 2002).  
 
 
Fig. 3. Schematic representation of A. camphorata-induced apoptosis in via intrinsic and 
extrinsic pathways 
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In recent years much interest has been focused investigation onto the cancer preventive 
compositions of A. camphorata rather crude extract. There are two review articles available, 
thus, extensively summarized potent bioactive components, which are present in A. 
camphorata (Ao et al., 2009; Geethangili & Tzeng, 2009). It is believed that the anti-cancer and 
anti-metastasis properties of this mushroom are derived from its diversified chemical 
constituents, although it is comprised primarily of two types of compounds: 
polysaccharides and triterpenes (Shao et al., 2008). Yeh et al. demonstrated that five 
lanostanes (dehydroeburicoic acid, 15ǂ-acetyl dehydrosulphurenic acid, 24-triene-21-oic 
acid, dehydrosulphurenic acid and sulphurenic acid) and three ergostane-type triterpenes 
(zhankuic acid, zhankuic acid-A and zhankuic acid-C) isolated from fruiting bodies of A. 
camphorata exhibits in vitro cytotoxic effect to various cancer cell lines, including MDA-MB-
231. Zhankuic acid and suphurenic acid showed significant cytotoxic effect to the human 
breast cancer cells MDA-MB-231 and MCF-7 with an IC50 value of 25.1 and 89.2; and 57.8 
and 357.0 µM, respectively. Indeed, sulphurenic acid is selectively cytotoxic to estrogen-
nonresponsive MDA-MB-231 cells, and the only one compound that does not contain the 
diene structure with in the rings at position 7 and 9 and instead possesses a single double 
bond in the rings at the position 8 (Yeh et al., 2009). This result also provides another 
hallmark that cytotoxic effect of bioactive compounds also depends on structural activity 
relationship. Antroquinonol, an ubiquinone derivatives, was isolated from the solid state 
fermented mycelium of A. camphorata exhibits cytotoxic effect against MDA-MB-231 and 
MCF-7 human breast cancer cells with an IC50 value of 2.64 and 2.1 µM, respectively (Lee et 
al., 2007). A very similar result were obtained from an another pure compound antrocin, 
isolated from the fruiting bodies of A. camphorata showed the most anti-proliferative effect 
against MDA-MB-231 and MCF-7 cells (Rao et al., 2011). Notably, non-tumorigenic breast 
epithelial MCF-10A cells were not affected by antrocin treatment.  
The morphological changes of human breast cancer (MCF-7) cells after A. camphorata 
treatment were further investigated to elucidate the underlying process of reduced viability 
treatment. The typical morphological characteristics for cell apoptosis, such as cell 
condensation, plasma membrane blabbing and formation of apoptotic bodies, were 
confirmed under phase contrast microscopy (Yang et al., 2006).  The hallmark of cell 
apoptosis, DNA fragmentation was also demonstrated in A. camphorata treated human 
breast cancer cells including MCF-7 and MDA-MB-231. Caspase-3 activity in A. camphorata-
treated MCF-7 breast cancer cells was shown to be increased, which further confirmed that 
A. camphorata could induce apoptosis in human breast cancer cells (Yang et al., 2006). An 
addition to A. camphorata crude extract, antrocin, a pure compound isolated from the 
fruiting bodies of A. camphorata significantly induced apoptosis in MDA-MB-231 breast 
cancer cells through the activation of caspase-3 (Rao et al., 2011). In vivo study, we showed 
that the tumor formation in BALB/c-nu mice with the implantation of MDA-MB-231 cells 
could be inhibited by the administration of the aqueous fermented culture broth of A. 
camphorata. The initial tumor development was dose-dependently inhibited by A. 
camphorata. The significant suppression of tumor development was directly demonstrating 
the in vivo anti-tumor effect of A. camphorata (Hseu et al., 2008). Comparably there was no 
cytotoxic effect was observed in control mice that received A. camphorata alone.  
The mechanism of apoptosis induced by A. camphorata with various cancer cell lines were 
extensively studied (Table. 1) and demonstrated the relevant pathways of apoptosis (Fig. 3). 
There is an increase of the Bax/Bcl-2 ratio associated with the apoptosis induced by A. 
camphorata treatment in MCF-7 and MDA-MB-231 cells (Fig. 3). MCF-7 cells exposed to A. 
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camphorata significantly enhanced Bax protein expression, whereas, Bcl-2 the anti-apototic 
protein was not affected (Yang et al., 2006). Rao et al. studied that antrocin, a pure 
compound isolated from the fruting bodies of A. camphorata markedly augmented Bax:Bcl-
2/Bcl-xL ratio in MDA-MB-231 cells (Rao et al., 2011). In an in vivo model, Bcl-2-positive 
cells were observed in MDA-MB-231 cells implanted cells mice tumor tissue. Furthermore, 
TUNEL assay showed that A. camphorata-induced Bcl-2 inhibition was directly proportional 
to apoptotic cells in mice tumor tissue (Hseu et al., 2008). This study also confirmed that A. 
camphorata-induced tumor suppression was mediated by cell-cycle arrest, as evidenced by 
reduction of cyclin-D and PCNA protein levels in mice tumor tissues. The down-regulation 
of Bcl-2 expression is known to be involved in the release of cytochrome c from 
mitochondria from the intrinsic pathway (Fig. 2). Further we investigated the A. camphorata-
induced mitochondria membrame permeability and cytochrome c release in MCF-7 cells. 
Cells treated with A. camphorata significantly increased cytochrome c accumulation in 
cytoplasm, which supports A. camphorata-induced mitochondrial membrane potential. This 
data also provided another possible mechanism that A. camphorata-induced apoptosis was 
mediated by mitochondrial membrane potential followed by cytochrome c release in human 
breast cancer cells (Yang et al., 2006).  
Another important mediator of apoptosis in immune cells is the Fas receptor/ligand 
signaling system. The critical elements of the Fas pathway that link receptor-ligand 
interaction and down-stream activation of caspases, including caspase-3, have been 
identified (Hung et al., 2010). Recent studies also indicate that widely used 
chemotherapeutic agents induce apoptosis in susceptible cells. Thereby, the 
chemotherapeutic agents required an alternative mediator. Recent studies revealed that 
Fas/Fas ligand (FasL) or death ligand/death receptor (DR) can activate the downstream 
extrinsic apoptotic pathway (Fig. 2). Gene expressions of both Fas/FasL were induced in 
human hepatoma HepG2 cells by treatment with methanolic extract of mycelium of A. 
camphorata. However, A. camphorata treatment dose-dependently inhibits death receptors 
(DR-4 and DR-5) and TNF-ǂ receptors (TNFR-I and TNFR-II) in HepG2 cells.  
Indeed, these results well demonstrate that A. camphorata induced apoptosis possibly by 
involving up-regulation of Fas expression, which promotes the ligation of Fas and FasL and 
then passes the death message to cytosolic messengers. As a result, procaspase-8 is activated 
to caspase-8, which triggers the caspase activation cascade. In addition, this study also 
demonstrates that A. camphorata-induced apoptosis was mediated by mitochondrial-
independent pathway (Song, 2005). 
4. A. camphorata up-regulates tumour-suppressor genes 
The p53 tumor suppressor gene encodes a multifunctional protein involved in the 
comphrehensive control of cellular responses to genotoxic stress. p53 mediated tumor 
suppressor effects are mediated by a variety of mechanisms including cell cycle arrest, 
apoptosis and cellular senescence that prevent cells with damaged DNA to pass on their 
genome to progeny. Recently much attention has been focused towards p53, because it is 
once of the main effectors of cell cycle check point. However, the precise molecular 
mechanisms of its action are still controversial. Several reports indicate that p53 directly 
arrest cells in G1 phase in response to DNA damage, thus preventing DNA synthesis from 
damaged templates (Wahl et al., 1997). Apart from this p53 is involved in regulating the cell 
cycle at transition of G1/S and G2/M and with in S phase (Talos & Moll, 2010). Evidence for 
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a possible role of p53 in M phase came from observations that p53 contributes to the control 
of centrosome duplication and to the prevention of DNA replication is impaired by spindle 
inhibitors (Talos and Moll, 2010).  
In recent reports indicate that both estrogen receptor positive (MCF-7) and triple negative 
(MDA-MB-231) breast cancer cells were exposed to synthetic or natural derived anti-cancer 
drugs remarkable arrest cell cycle via accumulation in G2/M phase through the inhibition of 
Akt activity and p53-independent or p53-dependent activation of p53 inducible proteins 
such as p21/p53R2 /CDKN1A and GADD45A (De Santi et al., 2011; Hahm et al., 2011; 
Hsieh et al., 2011). It is noteworthy that A. camphorata significantly up-regulates p53 tumor 
suppressor gene in human colorectal carcinoma cells (Lien et al., 2009), and human prostate 
cancer cell lines (Chen et al., 2007). However, the potential up-regulation of p53 tumor 
suppressor gene product by A. camphorata was yet to be illustrated in human breast cancer 
cell lines. Our current work is fascinating A. camphorata induced up-regulation of p53 in 
triple negative MDA-MB-231 cells. We believe coming future this result may give vital 
evidence that anti-tumor activity of A. camphorata through the up-regulation of p53 tumor 
suppressor gene.  
5. A. camphorata down-regulates invasion and metastasis 
Metastasis is characterized that the multistep processes by which cancer spreads from the 
place at which it first arose as a primary tumor to distant location and establish itself in a 
new site in the body through blood stream or lymphatic system. Metastasis depends on the 
cancer cells acquiring two separate abilities increased motility and invasiveness cells that 
metastasize are basically identical to the original tumor. For example if cancer arises in the 
breast and metastasizes to the lung, the cancer cells in lung are similar breast cancer cells. 
Normally our body has many safeguards to prevent cells from adverse cancerous effects. 
However, many cancer cells itself have the ability to overcome these safeguards. In recent 
years much research has been focused on to understanding how cancer cells are mutated to 
circumvent the body’s defenses and freely travel to another location. In normal tissue, cells 
adhere both to one another and a mesh of proteins are filled the space between them, this 
outer membrane proteins are known as extracellular matrix. The connection between cells 
and extracellular matrix is particularly characterized that from skin, mouth, lung, stomach 
and other organs. During invasion, cells spreads, it must break away not only from the cells 
around it, but also from the extracellular matrix. Cells are tightly bonded with cell-to-cell 
adhesion molecules. These adhesion molecules also allow interactions between numerous 
proteins on the cells surface. In cancerous cells, the adhesion molecules seem to be missing 
or compromised.  
Cadherins, a family of Ca2+-dependent intracellular adhesion protein molecules, which 
playing vital role for connecting two individual cells. Cadherins also regulates cells 
morphology, motility and hence tumor invasiveness. The cadherin molecules have three 
major regions. There is an extracellular region that mediates specific adherins, a 
transmembrane domain that spans the cell membrane, and a cytoplasmic domain that 
extends into the cell. The normal pattern of E-cadherin, ǂ-, ǃ-, Ǆ- and p20-catenin are strong 
membraneous staining with localization at the intracellular border of luminal cells. 
Abnormal (absent, reduced or localized to cell compartments other than cell membrane) 
expression of E-cadherin and catenin has been reported in various human cancers and has 
been associated with tumor progression. The degradation of ǃ-catenin involves its 
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phosphorylation through complex formation with tumor suppressor gene products such as 
adenomatous polyposis coli (APC), glycogen synthase kinase-3ǃ (GSK3ǃ) and axin 
(Davidson et al., 2000). In tumor cells, E-caherin is either partly or entirely missing. This 
allows tumor cells to detach from each other, and from the matrix which holds everything in 
place. Recent clinical studies reveled that E-cadherin is important to regulate metastasis. E-
cadherin-mediated cell-cell adhesion is associated with the progression of many carcinomas, 
including breast, bladder and squamous head and neck carcinomas (Davidson et al., 2000). 
Abnormal expression of E-cadherin and catenin is very common in lobular than ductal 
carcinomas. However, its expression appears not to be involved into the early stage of 
neoplasia but to correlate with high grade invasive ductal carcinoma (Nakopoulou et al., 
2002). Reduced expression of E-cadherin is seen in about 50% of ductal carcinomas of the 
breast and is associated with high histological grade, nodal metastases and poor prognosis. 
Addition to cadherins, a number of proteolytic enzymes contribute to the degradation of 
environmental barriers, such as the extracellular matrix and the basement membrane. Thus, 
degradation of the extracellular matrix and components of the basement membrane, 
mediated by the concerted action of proteinases, such as matrix metalloproteinases (MMPs) 
and urokinase plasminogen activator (uPA), play a critical role in tumor invasion and 
metastasis (Westermarck & Kahari, 1999).  
Increasing expression of MMP-2, MMP-9 and angiogenic cytokine vascular endothelial 
growth factor (VEGF) in human breast cancer cell lines including estrogen receptor positive 
(MCF-7), triple negative (MDA-MB-231) and ductal epithelial tumor (T47D) cells has been 
suggested to be associated with the highly metastatic potential of breast cancer (Shibata et 
al., 2002; H.S. Lee et al., 2008). The promoter region of MMP-2 contains various cis-acting 
elements, including potential binding sites for the transcription factors nuclear factor-kappa 
B (NF-κB), activator protein-1 (AP-1), and stimulatory protein-1 (SP-1) (Lin et al., 2010). NF-
kB is critically involved in tumor progression through transcriptional regulation of invasion 
related factors, such as MMP-2/MM-9, uPA and VEGF (Shibata et al., 2002; Yang et al., 
2011). In addition, the involvement of mitogen-activated protein kinase (MAPK) pathways 
in NF-kB activation has been demonstrated to play an important role in tumor metastasis 
(Yang et al., 2011). Therefore, the inhibition of MMPs- and/or uPA-mediated migration or 
invasion could be a potential treatment for preventing or inhibiting cancer metastasis.  
Once breast cancer has spread beyond the breast and under arm lymph nodes, it is 
considered a “systemic” disease, meaning that it is necessary to treat the whole body rather 
than just one particular spot. If breast cancer cells has traveled through the blood stream or 
lymphatic system, there are likely to be breast cancer cells in many different parts of the 
body, even scans only shows few spots. Therefore, the treatment that reaches all parts of the 
body. Chemotheraphy or hormonal therapy, are more suggestible treatment are used to 
treat metastic breast cancer instead of treatments that just treat one part of the body, just as 
surgery. In general, a women might be treated with a hormonal theraphy if she has a 
hormone responsive (estrogen or progesterone receptor positive) tumor, whereas, tumor 
that are not responsive to hormonal therapy, further choice is chemotherapy. There are 
many different types of chemotherapy that are used for breast cancer. In recent years, there 
has been much interest in developing new types of medicines that kill breast cancer cells in 
new and different way. Some of these drugs are only work against a specific type of breast 
cancer. To overcome this problem, current drug discovery system more fascinating a target 
protein or signaling cascades rather than specific type of breast cancer cells.  
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It was well demonstrated that metastasis is responsible for the majority of failures in cancer 
treatment, and is the major case of death from cancer. Therefore, chemotherapy is suggested 
to prevent local recurrence of the primary tumor and the spread of tumor cells (Weng & 
Yen, 2010). However, commercially available synthetic chemotherapeutic agents have severe 
side effects. Recent studies demonstrated that phytochemicals derived from plant source 
potentially prevents cancer metastasis (Sliva, 2008). As I mentioned that A. camphorata has 
been used in traditional Chinese medicine for various ills, including cancer. The 
mechanisms of action of A. camphorata against cancer cells includes inhibition of cell 
proliferation, induction of apoptosis and suppression of the motility of highly invasive 
breast cancer cells were intensively studied (Yang et al., 2006; Hseu et al., 2008). Although 
there are different compounds with various pharmacological activities were extracted from 
mycelia, fruiting bodies, spores and fermented culture broth of A. camphorata. The anticancer 
and anti-metastatic activities of this medicinal mushroom were primarily relied on its 
polysaccharide, benzenoids, lignans, diterpenes, triterpinod and steroid components (Ao et 
al., 2009; Geethangili & Tzeng, 2011).  
Our recent study was clearly demonstrated that the anti-invasive and anti-metastatic effects 
of A. camphorata against highly metastatic human breast cancer cells (MDA-MB-231) is due 
to the inhibition of invasion and metastasis regulatory proteins such as MMP-2, MMP-9, 
uPA, uPA receptor and VEGF through the down-regulation of MAPK/NF-κB signaling 
pathway (Yang et al., 2011). A. camphorata inhibits invasion and metastasis of breast cancer 
cells not only through the suppression of MMPs/uPA, it also enhance endogenous 
MMPs/uPA inhibitors, TIMP-1, TIMP-2 and PAI respectively. It is also well understood that 
A. camphorata potentially modulates MAPKs cascades (Geethangili & Tzeng, 2009). Our 
investigation also revealed that the inhibition of MMPs/uPA due to the down-regulation of 
MAPK cascades such as ERK1/2, JNK and p38. Further we observed the major MMP’s 
transcription factor NF-κB also significantly inhibited by A. camphorata treatment in MDA-
MB-231 human breast cancer cell (Yang et al., 2011).  
Moreover, there is substantial evidence on the inhibition of MMP-9/MMP-2 and 
suppression of invasiveness and metastases of cancer cells using various chemopreventive 
or chemotherapeutic agents (Ho et al., 2002; Abiru et al., 2002). Based on the observation, A. 
camphorata eventually decreased the activity or protein levels of tumor metastasis-related 
proteins, including MMP-9, MMP-2, uPA, and uPAR, and increase the expression of their 
endogenous inhibitors, TIMP-1, TIMP-2, and PAI-1, in MDA-MB-231 cells. Therefore, A. 
camphorata could be a potential agent for the prevention of breast cancer metastasis.  
6. A. camphorata down-regulates tumour angiogenesis 
Angiogenesis is the development of a new blood supply from an existing vasculature. 
Normal cells can stimulate new blood vessels to grow. This happens to repair damaged 
tissue when wounds are healing. Therefore, normal cells have genes that can produce 
proteins known as angiogenic factors, which switch blood vessels growth on. However, cells 
also have genes that produce certain molecules called anti-angiogenic factors, which slow 
down blood vessel growth (Papetti & Herman, 2002).  
Accumulating evidences indicate that progressive tumor growth is dependent on 
angiogenesis. It also plays an important role in the growth and spread of cancer. New blood 
vessels “feed” the cancer cells with oxygen and nutrients, allowing these cells to grow, 
invade nearby tissue, spread to other parts of the body, and form new colonies of cancer 
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cells (Maliwal et al., 2009). Every cancer begins its existence as a tiny cluster of abnormal 
tumor cells growing in an organ. Without its own blood supply to bring in oxygen and 
nutrients, the tumor cannot grow larger than 1-2 millimeters in diameter (about the size of a 
small pea). While this early stage of tumor growth can last for month or even years, 
eventually a few cancer cells gain the ability to produce angiogenic growth factors. These 
growth factors are released by the tumor into nearby tissues, and stimulate new blood 
vessels to sprout vigorously from existing healthy blood vessels toward and into the tumor. 
In addition, increased angiogenesis has also been observed in preneoplastic conditions 
(Sharma et al., 2001), indicating that it plays a key role in the early processes of 
carcinogenesis.   
Various angiogenic regulators have been identified since the introduction of angiogenesis in 
the scientific community. As we mentioned above that the stability of vasculature is highly 
regulated by the homeostasis between angiogenic stimulators and inhibitors. The best 
characterized angiogenic stimulators including, angiopoietin, vascular endothelial growth 
factor (VEGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), 
endothelial growth factor (EGE) and hepatocyte growth factor (HGF) (Liekens et al., 2001; 
Takeya et al., 2008). Number of research is going on onto anti-angiogenic therapy. The 
research has found that the amounts of these angiogenic factors are expressed very high at 
the outer edge of tumor. Anti-angiogenic drugs may stop a cancer from growing into 
surrounding tissue or spreading. They will probably not be able to get rid of a cancer, but 
may be able to halt new blood vessel growth and starve a tumor by cutting off its blood 
supply. There ate more than three hundred angiogenesis inhibitor molecules have been 
discovered so far: Some angiogenesis inhibitors are naturally present in the human body 
(endogenous angiogenic inhibitors) results healthy tissues appear to resist cancer growth by 
containing these antiangiogenic compounds. The endogenous angiogenic inhibitors are 
classified into five major groups; 1) endothelial cell specific inhibitors, 2) avascular tissue-
derived inhibitors, 3) anti-angiogenic cytokines, 4) angiogenic factor antagonists and 5) 
other inhibitors (Cao, 2001; Grant & Kullar, 2005). Other angiogenesis inhibitors occur 
naturally in substances found in green tea, soy beans, fungi, mushrooms, tree bark, shark 
tissues, snake venom and many other plants and animals. Still other angiogenesis inhibitors 
have been manufactured synthetically in the laboratory.  
Conventional chemotherapy preferentially targets rapidly dividing cancer cells. However, 
certain normally dividing cells (hair cells, intestinal cells, mucous membranes, bone marrow 
cells) are also destroyed, which causes the well-known severe chemotherapy side effects of 
hair loss, diarrhea, mouth ulcer, infection, and low blood counts. Some chemotherapy 
regimens work very well at treating cancers that are diagnosed early. Most of the anti-
angiogenic therapies targets only growing new blood vessel (endothelial) cells. Since blood 
vessels do not grow in normal, healthy tissues, the side effects of anti-angiogenic therapy are 
concentrated primarily at the cancer site. Most anti-angiogenic drugs do not kill cancer cells 
directly and are therefore better tolerated compared to chemotherapy, with fewer and less 
severe side effects. To keep cancers from re-growing, it is possible that some patients may 
need to take anti-angiogenic drugs as a chronic therapy, although this hypothesis is still 
being tested in clinical studies. In response to targeted affects anti-angiogenic agents are 
classified into three major class; they are 1) agent that block new bllod vessel from sprouting 
(true angiogenic inhibitors), 2) assault a tumor’s established blood supply (vascular 
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targeting agents) and 3)  attack both the cancer cells as well as blood vessel cells (the double-
barreled approach). Recent clinical studies in different cancer types have shown that anti-
angiogenic therapy generally works best when used in combination with cytotoxic 
chemotherapy or radiation. Most experts believe that such combinations will ultimately 
provide cancer patients with the greatest benefit. 
A recent study has shown that ethyl acetate extracts of fruiting bodies of A. camphorata not 
only suppressed tumor growth in human liver cancer cell PLC/PRF/5 xenografted male 
BALB/cA-nu nude mice, but also inhibits tumor angiogenesis (Hsu et al., 2007). It is now 
known that a decrease in tumor size is often associated with inhibited microvessel formation 
in the tumor. This study also confirmed that PLC/PRF/5 cells implanted mice greatly 
induced angiogenesis and the hemoglobin levels (6.4-fold). The amount of hemoglobin level 
in tumor tissue is considered as a blood vasculature in tumor tissue. However, mice were 
pretreated with A. camphorata significantly inhibits PLC/PRF/5 cells-induced angiogenesis 
and hemoglobin level in mice tumor tissue (Hsu et al., 2007).    
Subsequently, polysaccharides were isolated from the mycelium or fermented culture broth 
of A. camphorata showed potent anti-tumor activity in several in vitro and in vivo models 
(Liu et al., 2004). Tumor growth and metastasis is angiogenesis dependent. Several lines of 
direct evidence have shown that angiogenesis is essential for tumor growth and metastasis 
(Weng & Yen, 2010). The ex vivo check chorioallatonic membrane (CAM) assay is commonly 
employed to examine the anti-angiogenic activity of samples. Polysaccharides with different 
molecular weight, isolated from A. camphorata were tested for its anti-angiogenic properties 
using CAM assay. The microvasculature was markedly reduced after treatment with 
polysaccharides (Yang et al., 2009). In addition to CAM assay, Tube forming assays measure 
a complex series of events involving changes in endothelial cell morphology and migration, 
leading to the formation of a complex interconnecting network of capillary tubes with 
identifiable lumens (branching morphogenesis) (Cavell et al., 2011). Polysaccharides from A. 
camphorata also significantly inhibit matrigel-dependent capillary tube formation in human 
umbilical vein endothelial (HUVEC) cell and bovine aortic endothelial cells (Yang et al., 
2009; Chen et al., 2005; Cheng et al., 2005).  
Angiogenesis requires endothelial proliferation, migration, and tube formation. Cancer cells 
are able to produce large amounts of several angiogenic factors including VEGF, EGF, FGF 
(Liekens et al., 2001). Therefore, VEGF is considered as an important biomarker of 
angiogenesis. Over expression of VEGF in tumors increases tumor vascularization and 
growth, while capturing VEGF or blocking its signaling receptor, VEGFR-2, by VEGF 
receptor tyrosine kinase inhibition, antisense oligonucleotides, vaccination, or neutralizing 
antibodies reduces tumor angiogenesis and growth. Besides, VEGF induces cyclin D1 
expression, which serves as a cell cycle regulatory switch in actively proliferating cells, 
through PLCg-PKC-MAP kinase pathways. Further to confirm the anti-angiogenic activity 
of A. camphorata the inhibition of VEGF-R tyrosine kinase phosphorylation was monitored. 
Similarly, polysaccharides from A. camphorata have been shown to suppressed VEGFR-2 
tyrosine kinase phosphorylation in Tyr1054/1059 residual position.  This study also 
revealed A. camphorata significantly inhibits endothelial cell proliferation as evidenced by 
the reduction of cyclin-D1 protein expression, which is a marker of cell cycle check point 
(Cheng et al., 2005). These results indicate that A. camphorata might be a potent inhibitor of 
angiogenesis and subsequent tumor promotion.  
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7. A. camphorata down-regulates NF-κB/AP-1 signalling pathway 
7.1 Inhibits NF-κB activation 
NF-κB (Nuclear Factor-KappaB) is a heterodimeric protein composed of different 
combinations of members of the Rel family of transcription factors. NF-κB dimers are 
sequestered in the cytosol of un-stimulated cells via non-covalent interactions with a class of 
inhibitor proteins, called I-κBs. Signals that induce NF-κB activity cause the phosphorylation 
of I-κBs, their dissociation and subsequent degradation, thereby allowing activation of the 
NF-κB complex. The degradation of I-κB proteins that permits NF-κB molecules to move 
into the nucleus is also carried out by the proteasome but only after prior phosphorylation 
of I-κB by the IKKs. NF-κB can be activated by exposure of cells to LPS or inflammatory 
cytokines such as TNF-ǂ or IL-1, growth factors, lymphokines, and by other physiological 
and non physiological stimuli (Li & Verma, 2002; Verma, 2004).  
The Rel/NF-κB family of transcription factors are involved mainly in stress-induced, 
immune, and inflammatory responses. In addition, these molecules play important roles 
during the development of certain hemopoietic cells, keratinocytes, and lymphoid organ 
structures (Matsumori, 2004). Moreover, NF-κB family members have been implicated in 
neoplastic progression and the formation of neuronal synapses (Matsumori, 2004). NF-κB is 
also an important regulator in cell fate decisions, such as programmed cell death and 
proliferation control, and is critical in tumorigenesis (Thu & Richmond, 2010). An another 
study showed that angiocidin, which shown anti-tumor activity by blocking angiogenesis in 
various cancer cells through the suppression of NF-ĸB. However, in MDA-MB-231 cells, 
angiocidin significantly activate NF-ĸB and the de novo up-regulation of many down-
stream genes transcribed by NF-ĸB, including cytokines, inflammatory mediators and the 
cell cycle inhibitor p21(waf1) (Godek et al., 2011). 
The molecular identification of its p50 subunit (v-REL) as a member of the 
reticuloendotheliosis (REL) family of viruses that provided the first evidence that NF-κB is 
linked to cancer (Prasad et al., 2010). Although the transforming ability of the v-REL 
oncoprotein was established many years ago, recent evidence suggests other human NF-κB 
family members may be important in oncogenesis (Dolcet et al., 2005). NF-κB DNA binding 
activity is constitutively increased in many lymphoid and epithelial tumors. The RAS, BCR-
ABL, and HER2 oncogenes and transforming viruses can activate NF-κB. Furthermore, 
several genes thought to be essential to the cancer phenotype those controlling angiogenesis, 
invasion, proliferation, and metastasis, contain κB binding sites.  
Research over the past decade has revealed that NF-κB is an inducible transcription factor 
for genes involved in cell survival, cell adhesion, inflammation, differentiation and growth. 
Many of the target genes that are activated are critical to the establishment of early and late 
stages of aggressive cancers such as expression of cyclin D1, apoptosis suppressor proteins 
such as Bcl-2 and Bcl-XL and those required for metastasis and angiogenesis such as MMPs 
and VEGF (Dorai & Aggarwal, 2004). Higher concentration of serum VEGF has been shown 
to associate with a poorer prognosis in patients with breast cancer. On the other hand, 
constitutive expression of a transcription factor, NF-κB was correlated with progression and 
metastasis in a number of human breast cancers, suggesting a possible regulation of VEGF 
expression by NF-κB. Shibata et al. analyzed the expression of VEGF and constitutive NF-κB 
activity in three breast cancer cell lines, MCF-7, T47D, and MDA-MB-231. The basal levels of 
VEGF mRNA expression correlated with those of nuclear NF-κB activity in these cell lines. 
The highest NF-κB activity in MDA-MB-231 cells was associated with the highest expression 
www.intechopen.com
Multiple Molecular Targets of Antrodia camphorata: 
A Suitable Candidate for Breast Cancer Chemoprevention 
 
173 
of VEGF mRNA, while the activity and the mRNA levels were moderate in MCF cells and 
the lowest in T47D cells (Shibata et al., 2002).  A similar study showed that the triple 
negative breast cancers (MDA-MB231 and MDA-MB-468) or MCF-7 and T47D implanted 
mice expressed higher VEGF and NF-κB activation in their tumor tissues (Chougule et al., 
2011; Antoon et al., 2011). Recently, Ambs and Glynn revived that inducible nitric oxide 
synthase (iNOS) has been observed in many types of human tumors. In breast cancer, 
increased iNOS is associated with markers of poor outcome and decreased survival. iNOS 
induction will trigger the release of variable amounts of NO into the tumor 
microenvironment and can activate oncogenic pathways, including the Akt, epidermal 
growth factor receptor and c-Myc signaling pathways, and stimulate tumor 
microvascularization. More recent findings suggest that NO induces stem cell-like tumor 
characteristics in breast cancer. This review, also pointed that NF-κB is the key transcription 
factor which playing major role for the production of NO via iNOS expression in various 
breast cancer cell lines (Ambs & Glynn, 2011). The over expression of metallothionein-2A 
(MT-2A) is frequently observed in invasive human breast tumors and has been linked with 
more aggressive breast cancers. MT-2A over expression led to the induction of MDA-MB-
231 breast cancer cell migratory and invasive abilities. Concomitantly, they observed the 
expression of matrix metalloproteinase-9 (MMP-9) and the transcriptional activity of AP-1 
and NF-κB were upregulated by MT-2A overexpression in MDA-MB-231 cells (Kim et al., 
2011).  
7.2 Inhibits AP-1 activation 
Activated protein-1 (AP-1) is another transcription factor that regulates the expression of 
several genes that are involved in cell differentiation and proliferation. Functional activation 
of the AP-1 transcription complex is implicated in tumor promotion as well as malignant 
transformation. This complex consists of either homo or heterodimers of the members of the 
JUN and FOS family of proteins (Surh, 2003). This AP-1 mediated transcription of several 
target genes can also be activated by a complex network of signaling pathways that involves 
external signals such as growth factors, mitogen activated protein kinases (MAPK), 
extracellular-signal regulated protein kinases (ERK) and JUN-terminal kinases (JNK). Some 
of the target genes that are activated by AP-1 transcription complex mirror those activated 
by NF-κB and include Cyclin D1, bcl-2 , bcl-XL, VEGF, MMP and urokinase plasminogen 
activator (uPA) (Dorai & Aggarwal, 2004). Expression of genes such as MMP and uPA 
especially promotes angiogenesis and invasive growth of cancer cells. Most importantly, 
AP-1 can also promote the transition of tumor cells from an epithelial to mesenchymal 
morphology which is one of the early steps in tumor metastasis. These oncogenic properties 
of AP-1 are primarily dictated by the dimer composition of the AP-1 family proteins and 
their post-transcriptional and translational modifications.  
7.3 Inhibits COX-2 activity 
Several preclinical studies indicated the importance of regulation of cyclooxygenase-2 
(COX-2) expression in the prevention and the treatment of several malignancies. This 
enzyme is overexpressed in practically every pre-malignant and malignant condition 
involving the colon, liver, pancreas, breast, lung, bladder, skin, stomach, head and neck and 
esophagus (Aggarwal et al., 2006). Overexpression of this enzyme is a consequence of 
deregulation of transcriptional and post-transcriptional control. Depending upon the 
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stimulus and the cell type, different transcription factors including AP-1, NF-IL-6, NF-κB 
can stimulate COX-2 transcription (Surh, 2003). Wild type p53 protein expression can 
suppress COX-2 transcription while the mutant p53 protein can not. Consistent with this 
observation, increased COX-2 levels are seen in several epithelial cancers that express 
mutant p53. Taken together, these findings suggest that the balance between the activation 
of the oncogenes and the inactivation of the tumor suppressor genes and expression of 
several pro-inflammatory cytokines can modulate the expression of COX-2 in tumors. 
Complicating matters further is the fact that conventional cancer therapies such as radiation 
and chemotherapy can induce COX-2 and prostaglandin biosynthesis. Thus, inhibition of 
this enhanced COX-2 activity in tumors clearly has a therapeutic potential.  
Accumulating evidence to implicate COX-2 function in breast cancer tumorigenesis. 
Soslowe et al. examined that 56% of infiltrating mammary carcinomas and intraductal 
carcinomas expressed significant levels of COX-2, while benign breast tissue at least 1 cm 
from a malignant lesion did not express COX-2 (Soslow et al., 2000). In a murine model of 
metastatic breast cancer, PGE2 levels are positively correlated with increased tumorigenic 
and metastatic potential (Kundu et al., 2001).  Perhaps the most convincing evidence that 
COX-2 causes breast cancer in animals comes from transgenic mice in which COX-2 was 
overexpressed in mammary tissue by using the mouse mammary tumor virus (MMTV) 
long-terminal repeat promoter. More than 85% of these mice developed tumors, indicating 
that COX-2 overexpression alone is sufficient to cause breast tumors (Liu et al., 2001). 
Ristimaki et al. analyzed the expression of COX-2 protein by immunohistochemistry in 
tissue array specimens of 1576 invasive breast cancers. Moderate to strong expression of 
COX-2 protein was observed in 37.4% of the tumors, and it was associated with unfavorable 
distant disease-free survival. Elevated COX-2 expression was associated with a large tumor 
size, a high histological grade, a negative hormone receptor status, a high proliferation rate 
(identified by Ki-67), high p53 expression, and the presence of HER-2 oncogene 
amplification, along with axillary node metastases and a ductal type of histology (Ristimaki 
et al., 2002). These results indicate that elevated COX-2 expression is more common in breast 
cancers with poor prognostic characteristics and is associated with an unfavorable outcome. 
Therefore the breast cancer treatment also targeted inhibition of COX-2 activity.  
A. camphorata extract and its bioactive compounds, polysaccharides and triterpenoids, have 
been shown to have anti-proliferative, anti-invasive or anti-metastatic activities were 
observed in various cell lines or animal models. These investigations also revealed the A. 
camphorata regulation on signaling pathways or transcription factors, especially NF-κB 
involved in the effects of anti-angiogenesis, anti-adhesion and anti-invasion (Fig. 3). 
Moreover, the mechanism induced by A. camphorata with various cancer cell lines was well 
understood. We also contributed to understand the mechanism involved in breast cancer 
cells. Triple negative human breast cancer cells, MDA-MB-231 were treated with fermented 
culture broth of A. camphorata induced apoptosis followed by the regulation of Bax:Bcl-2 
ratio.  The induction of apoptosis was directly correlated with down-regulation of COX-2 
expression in MDA-MB-231 cells (Hseu et al., 2007). This data supports A. camphorata-
induced apoptosis might be associated with the inhibition of COX-2 activity. Very recently, 
we also observed that the fermented culture broth extracts of A. camphorata inhibit invasive 
behavior of breast cancer MDA-MB-231 cells through suppressing degradation of ECM, 
down-regulating the expression of MMPs, including MMP-9 and MMP-2; uPA and uPAR 
expression. This study also provided positive evidence that the inhibition of MMP-2, MMP-
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9, uPA and uPAR in MDA-MB-231 cells by A. camphorata is through the down-regulation of 
MAP kinase cascades, including ERK1/2, JNK1/2 and p38. In addition, we also found that 
the inhibition of MAPKs further suppressed NF-κB nuclear translocation (Yang et al., 2011). 
Similar NF-κB, AP-1/MAPK and COX-2 inhibitory activity of A. camphorata was observed in 
various cancers and activated cell lines as summarized in (Geethangili & Tzeng, 2009; Ao et 
al., 2009). However, still certain molecular mechanisms are yet to be understood, especially 
the involvement A. camphorata in AP-1 transcriptional activation of inhibition in human 
breast cancer cells.  
 
 
Fig. 4. NF-κB mediated anti-cancer activity of A. camphorata 
8. Future perspectives 
In past two decades A. camphorata received pioneering interest for their pharmacological 
intervention s. It is oblivious that A. camphorata exhibits anti-cancer activity against human 
breast cancer cell lines, including estrogen receptor-positive (MCF) and triple-negative 
(estrogen, progesterone and Her-2) MDA-MB-231 cell lines in vitro and in vivo.  The 
pronounced anti-cancer activity was highly connected with its anti-metastasis, anti-
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angiogenic, and the inhibition of cell cycle progression; and the induction of apoptosis in 
both intrinsic and extrinsic pathways. Besides, A. camphorata possessed various chemical 
components such as polysaccharides, triterpenes, diterpenes, benzinoids and steroids may 
be the bioactive compounds responsible for the observed anticancer activity against human 
breast cancer cells. Still, there are number compounds which presented A. camphorata are 
warranted to extensive study.  The presented evidences are confirmed that A. camphorata as 
a potential candidate for breast cancer chemoprevention. However, the chemopreventive 
agents can be used not just to prevent cancer but also treat cancer. Since, the 
pharmacological safety, most chemopreventive agents to enhance the effect at lower dose 
and thus can minimize chemotherapy-induced toxicity to non-cancer cells. It was cleared 
that A. camphorata failed to induce cytotoxic effect against non-cancer cell lines. And the 
notable point is certain human breast cancer cells are resistance to hormonal therapy or 
chemotherapy. Thus, agents that can suppress multiple pathways have great potential for 
the treatment of human breast cancer.  A. camphorata achieved the target that it can inhibit 
cancer development in multiple signaling pathways.  
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